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ABSTRACT 
Conduct Disorder and Future Substance Abuse:  
Factors Affecting Drug Treatment Outcome 
 
Matthew E. Goldfine 
 
Prior research has demonstrated a relation between Conduct Disorder (CD), its severity (total 
number of symptoms), and substance use disorder (SUD). The current study examined 105 
opioid dependent adults for a history of CD and treatment outcome characteristics over a 16 
week SUD treatment program. Results demonstrate the effects of CD in regards to poorer 
improvement of summed Addiction Severity Index composite scores and amphetamine use. 
Improvement in cocaine use was found to be associated with a CD diagnosis. CD severity was 
found to lead to poorer improvement as measured by psychiatric impairment and alcohol 
intoxication. However, participants with increased CD severity were more likely to decrease 
sedative and cocaine use over the course of treatment. A history of CD and violent behavior was 
not shown to affect treatment outcome. No treatment retention or urine sample analyses 
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Conduct Disorder and Future Substance Abuse:  
Factors Affecting Drug Treatment Outcome 
 The presence of a comorbid mental health disorder among substance users has been 
shown to lead to higher rates of drug use, increased relapse rates, and overall poor treatment 
outcome (Tomlinson, Brown, & Abrantes, 2004). Studies demonstrate that 64% of substance 
abusers have a lifetime comorbid Axis I disorder (Wise, Cuffe, & Fischer, 2001). Often the most 
common comorbid Axis I disorder diagnosed among substance users is Conduct Disorder (CD; 
Grella et al., 2001). For instance, up to 52% of children and adolescents with CD will at some 
point meet criteria for a Substance Use Disorder (SUD; Reebye, Moretti, & Lessard, 1995). 
Furthermore, substance users with CD tend to use and abuse drugs at higher rates than those with 
other comorbid disorders (Disney, Elkins, McGue, & Iacono, 1999). Considering the ample 
support for the co-occurrence of CD and SUD (e.g., Armstrong & Costello, 2002), there are 
relatively few studies which discuss how CD may influence the course of substance abuse or the 
prognosis for those with both CD and SUD. The present study further examined the association 
between CD and the functioning and treatment outcome among a population of opioid dependent 
adults seeking treatment.  
The American Psychiatric Association’s (APA) Diagnostic and Statistical Manual: 4th 
edition, Text Revision (DSM-IV; 2000) defines CD as the persistent pattern of disregard for the 
basic rights of others. A diagnosis of CD is predictive of multiple negative outcomes, such as 
Adult Antisocial Personality Disorder (Ridenour et al., 2002), poor educational achievement, 
welfare dependency (Zoccolillo, Paquette, Azar, Cote, & Tremblay, 2004), and adult criminality 
(Simonoff et al., 2004). However, there is large variation in the expression of CD symptoms 
among those who have been diagnosed. Four separate clusters of symptoms exist, including: 
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aggression, property destruction, theft, and defiance of societal norms (APA, 2000). Only three 
of fifteen possible symptoms—from any of the above four clusters—are needed for diagnosis of 
CD. Thus, one who is truant from school, runs away from home, and frequently lies will have the 
same diagnosis as one who bullies others, has used a deadly weapon, and committed rape. The 
variability in the presenting symptoms of a CD diagnosis presents a problem for predicting how 
those with CD and an SUD may progress though substance abuse treatment and recovery. It 
seems unlikely that any and all combinations of symptoms would lead to similar substance use 
patterns and treatment outcomes. While no studies have directly measured the relation between 
SUD treatment outcomes and specific symptom clusters of CD, some researchers have 
investigated the relation between aggression, rape, truancy, and theft—all  of which are CD 
symptoms—and found that each is uniquely predictive of SUD. If certain clusters of CD 
symptoms are stronger predictors of SUD development or treatment outcome, the dissemination 
of such knowledge would likely improve overall SUD prevention and treatment. 
Prior to elaborating on the effect of specific CD symptoms on SUD, a relation between 
the two first must be established. In one study seeking to examine the deleterious consequences 
of CD on later adult functioning, Fergusson, Horwood, and Ridder (2005) investigated general 
adult functioning among participants who, as children, were assessed for various conduct 
problems. CD-like symptoms (but not a diagnosis of CD) at ages 7-9 were measured and various 
outcome data were collected regarding risky behavior at ages 21-25. At baseline, increased 
conduct problems were significantly correlated with lower IQ, lower socioeconomic status, and 
general family distress. Controlling for these possible confounding variables, the authors found 
an increased likelihood that the children with more CD-like symptoms at ages 7-9 were more 
involved with delinquency, risky sexual behavior, drug use, and internalizing disorders at ages 
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21 - 25. Furthermore, while male and female differences were found concerning the average 
number of CD-like symptoms, the relation between childhood conduct problems and poor adult 
functioning remained the same. Although the study did not focus on substance abusing adults, it 
nevertheless supports the hypothesis that childhood conduct problems contribute to a range of 
negative outcomes in adulthood. Whitmore, Mikulich, Ehlers, and Crowley (2000) displayed 
similar support of gender’s minimal effects on CD and SUD. The authors found that adolescent 
females with CD demonstrated similar drug use rates at intake as well as similar treatment 
outcomes to those of males with CD. It appears that both males and females with CD and SUD 
exhibit similar behaviors relating to overall functioning following treatment.  
Whereas general adult functioning appears to be negatively impacted by CD, there 
appears to be a particular link between CD and the development of SUD. In general, CD 
symptoms have been shown to precede the initiation of substance use (Hser, Grella, Collins, & 
Teruya, 2003; Windle, 1990). In a longitudinal analysis of mental health disorders as predictors 
of future substance use, Boyle and colleagues (1992) found that only CD independently 
accounted for the future development of marijuana and hard drug use. This effect remained even 
when prior drug use was statistically controlled. Armstrong and Costello (2002) confirmed CD’s 
link with future SUD and suggested that a diagnosis of CD is strongly related to earlier initiation 
of drug use and future SUD. Furthermore, Ridenour and colleagues (2002) found that not only 
does childhood CD predict later SUD problems, they also demonstrated that the age of onset of 
CD problems has little effect on future drug and alcohol-related symptoms; both childhood and 
adolescent onset CD are equally predictive of future SUD.  
A number of studies have shown that CD is also a strong predictor of the use of specific 
substances, even when other possible constructs are statistically controlled. For example, in an 
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investigation of CD symptoms in childhood, Fergusson, Lynskey, and Horwood (1993) found 
that cannabis use before the age of 15 was significantly correlated with parent and teacher report 
of CD symptoms at age 8. Additionally, when variables such as family socioeconomic status and 
parental divorce and conflict were controlled, children with high ratings of CD-related symptoms 
were almost three times more likely to use cannabis than similarly aged children with fewer CD 
symptoms. Despite prior beliefs that CD’s relation to later substance use was spurious and that 
other variables (family or social characteristics) were the cause of both, the authors concluded 
that conduct problems and not family or social characteristics significantly accounted for future 
cannabis use. In addition to cannabis, past studies have demonstrated that CD leads to higher 
rates of abusing alcohol (Myers, Brown, & Mott, 1995), nicotine (Disney et al., 1999), cocaine, 
amphetamines (Whitmore et al., 2000), opioids, hallucinogens, and inhalants (Crowley, 
Mikulich, MacDonald, Young, & Zerbe, 1998). In comparison to most recent prevalence 
measurements (Substance Abuse and Mental Health Services Administration, 2005), users with a 
history of CD are anywhere from 1.5 to 50 times as likely to use a harmful substance.  
In addition to increasing the likelihood of substance use, a growing literature is 
suggesting that CD may predict poor outcome for those who enter treatment for a SUD. Hser and 
colleagues (2003) conducted one of the first studies to directly compare SUD treatment outcome 
among adolescents with CD. A total of 1031 adolescents treated for SUD were assessed for CD 
at intake and various treatment outcome measures were taken a year later. Patients with CD in an 
outpatient or short-term inpatient program were more likely to drop out of treatment than the 
unimpaired comparison group. Moreover, after treatment, the patients with CD were more likely 
than patients without CD to use marijuana and hallucinogens, perform illegal activities, and be 
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arrested. These data demonstrate that after SUD treatment, adolescents with CD continue to 
engage in behavior detrimental to improvement at higher rates than adolescents without CD.  
Another salient analysis discussing the relation of CD and SUD treatment includes Myers 
and colleagues’ (1995) study measuring alcohol and drug abuse during adolescence. In this 
study, CD-related behaviors, the most common being deception or non-confrontational theft and 
the rarer being aggression, were typically exhibited before one’s first substance use. The authors’ 
main finding was that a history of CD-related symptoms leads to poor outcome in regards to 
post-treatment alcohol use, but not drug use. In other words, post-treatment rates of alcohol use 
differed among adolescents with and without preadolescent CD, but drug use rates did not 
statistically differ. Since post-treatment substance use was universally low for both groups, the 
lack of variation may explain treatment effects. A shortcoming of this study, as well as of the 
other studies discussed, is the lack of an evaluation of specific CD symptoms and SUD treatment 
outcome. In other words, these studies examine the relation between a diagnosis of CD–
regardless of the individual symptoms which comprise this diagnosis—and SUD development 
and treatment outcome. This raises the question of weather certain symptoms of CD (e.g., 
aggression) may be predictive of SUD treatment outcome whereas others (e.g., deceitfulness) 
may have little or no effect.  
Continuing the scrutiny of CD and its characteristics which may affect SUD treatment is 
a study conducted by Crowley and colleagues (1998). The authors break down features of CD, 
such as its severity and age of onset, and analyze how each may predict maladaptive behavior 
after receiving SUD treatment. Adolescent males were assessed through a series of intake 
measures which included a diagnostic interview, depression assessment, and a drug use query. 
Participants were then followed-up at 6, 12 and 24 months after admission using similar 
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evaluations. It was found that intake CD severity, that is, the total number of CD symptoms, was 
related to CD symptoms two years later. The authors concluded that increased CD symptoms led 
to poorer outcome two years after treatment. Similarly, earlier onset of CD, predicted overall 
criminal activity and delinquent behavior. Whereas Attention-Deficit/Hyperactivity Disorder 
(ADHD) and depression severity were also measured, only CD variables led to negative outcome 
in adolescent substance abusers.  
While Crowley and colleagues (1998) measured accompanying features of CD, the 
literature has begun to measure specific CD symptoms and the effect on the development and 
treatment of SUD. Among the many individual symptoms of CD which may lead to SUD, 
aggression and violence appear to be particularly powerful predictors. Burr (1987) reports a 
theoretical model which appears to have support within the literature. Namely, that violent 
behavior leads to future SUD. Burr theorizes that aggressive individuals often lead a lifestyle of 
criminality in which alcohol and drug use are common. Since the individual is already engaging 
in harmful behavior (violence), substance use is appealing because such activities correspond 
with a delinquent lifestyle. Johnston, O’Malley, and Eveland (1978) elaborate, claiming that 
violent characteristics lead one to spend time in an environment with other violent individuals 
where drug use is both expected and reinforced. Evidence confirming the link between violent 
behavior and future substance use is ample and often builds upon a study by White, Brick, and 
Hansell (1993). Over the course of nine years, 431 adolescents, 12 years-old at the start of 
assessment, were monitored for aggressive behavior (e.g., number of fights, use of a weapon) 
and alcohol use (e.g., drinking frequency, amount consumed). While alcohol use did not predict 
future aggression, violent behavior was shown to lead to increased alcohol use at an older age.  
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Further support of the predictive strength of childhood aggression to later SUD is 
demonstrated by Brook, Whiteman, Finch, and Cohen (1996). Pre-adulthood variables were 
measured over the course of a 20 year study to discern meaningful predictors of adult drug use. 
Childhood aggression, as measured by mother report, foreshadowed future adult substance use in 
both males and females. Kellam and Brown (1982) and Lewis, Robins, and Rice (1985) also 
support similar results. Both studies measured aggression in young children and found that it 
predicted adolescent and adulthood SUD. O’Donnell, Hawkins, and Abbott (1995), concluded 
similarly, but noted that not all aggressive children develop adult SUD. In other words, there are 
other specific qualities of the child or aggressive behavior that may contribute to one’s future 
outcome. It may be that frequency of aggressive symptoms or varied forms of aggression are 
better predictors than violent behavior in general.  
An example of an alternate form of violence is sexual assault or rape. Although little 
research has been done regarding the link between committing rape and substance abuse, a 
preliminary study (Abracen, Looman, & Anderson, 2000) compared sexually and non-sexually 
aggressive adults and their rates of alcohol and overall substance use. Although the temporal 
occurrence of the violence and alcoholism was difficult to distinguish, sexual offenders had 
higher rates of alcohol abuse than aggressive adults who have not engaged in prior sexual 
assault. Given that aggression alone is a risk factor for adult alcoholism (White et al., 1993) and 
sexual offenders have an even higher rate of alcoholism than non-sexual violent offenders, 
sexual violence, such as rape, which is one of the violent cluster symptoms of CD, may have a 
unique association with future alcoholism. 
Aggressive behavior is one of only a few specific CD symptoms demonstrated to predict 
SUD over time. However, there is also evidence that truancy and running away, both listed 
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within the defiance of social norms cluster of CD symptoms (APA, 2000), may be risk factors 
for future drug use and abuse. Truancy, or the act of missing school without parental permission 
(sometimes referred to as playing hooky), has been shown to be highly correlated with the use of 
cigarettes, alcohol, marijuana, cocaine, and other illicit substances. Miller and Plant (1999) 
studied 15-16 year-old adolescents from the United Kingdom and their truant behavior over the 
past month and lifetime alcohol, cigarette, inhalant, cannabis, and other drug use. For all 
substances, a significant association was found between drug use and truant behavior such that 
higher rates of missing school was correlated with higher rates of substance use. While there 
were other measured factors, such as parental discipline and style, which may also have 
accounted for increased substance use, truancy appears to be a relevant variable in the relation. 
Adding to the evidence demonstrating the effects of truant behavior on SUD is Brown, 
Schulenberg, Bachman, O’Malley, and Johnston’s (2001) analysis of about 188,000 high school 
seniors from 1976-97. Despite possible cohort differences, truancy was a fairly consistent 
predictor of cigarette, alcohol, marijuana, and cocaine use. The authors added that these results 
with such a large sample size reflect with confidence that truancy is a significant risk factor for 
SUD and treating truant individuals may be an important aspect of preventing and treating 
substance use. A caveat in both studies is that the participants’ age ranged from 15-18 years old. 
Diagnostic criteria for CD specify that these behaviors must occur prior to age 13. However, no 
data were collected prior to that critical age. 
In a review of adolescents who run away from home, Brennan, Hulzinga, and Elliot 
(1978) discuss substance abuse among this population. Before and during the act of running 
away, substance use is quite common and runaways may become drug dealers as a way of 
financial support. While there is a correlation between running away and SUD, it may be that 
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substance use and running away affect one another in a bidirectional manner. For example, the 
act of running away may lead one to be more involved within the drug culture while substance 
use may also be an indicator of general delinquency which leads one to leave home (and its 
rules) in order to continue deviant behavior. Similarly, delinquent behavior involving theft, 
another symptom cluster of CD, and SUD has also been theorized to exist in a reciprocal manner. 
Mason and Windle (2002) analyzed over 1,200 adolescents and found that such a bidirectional 
theory was supported for males. General delinquent behavior, such as theft, accounted for a 
minimal, yet significant, variance of one’s substance use, which, in turn, was predictive of 
continued future delinquency. The conclusion that theft may have only a small effect on future 
substance use is a noteworthy finding. It may be that theft-related symptoms of CD are not as 
relevant as aggression or truancy in predicting future substance abuse or SUD treatment 
outcome. 
The Present Study 
Throughout the CD literature, there appears to be strong support regarding the effect of 
CD on SUD development and treatment outcome. Boyle and colleagues (1992), recognizing this 
association, declared that it is imperative for future SUD studies to incorporate aspects of CD 
into their design. Despite strong recommendations and seemingly high clinical utility, no 
research could be found investigating specific or clusters of symptoms of CD and their predictive 
strength for SUD treatment outcome. Generally, studies assess the presence or absence of a CD 
diagnosis. Given the wide variation within a CD diagnosis, it would appear to be beneficial to 
identify specific clusters of symptoms that are related to the development and treatment of SUD. 
In an effort to build upon past research and to confirm past findings, the present study examined 
the relation between CD, its severity, and aggressive symptoms and SUD treatment outcome.  
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The goals of the study were threefold: (1) Determine if a diagnosis of CD leads to poorer 
SUD treatment outcome than the absence of CD, (2) Examine if the number of CD symptoms 
(severity) is predictive of poor treatment outcome, and (3) Analyze participants who exhibit CD 
with violent or aggressive symptoms versus those without such symptoms and their treatment 
outcome. The first two goals intended to replicate past studies. Namely, Hser and colleagues 
(2003) and Crowley and colleagues (1998) supported that a CD diagnosis and increased CD 
severity are linked with poor SUD treatment outcome, respectively. Regarding the third aim, in 
accordance with Loeber and colleagues’ (1995) findings that physical aggression, as opposed to 
other CD symptoms, were predictive of future CD development, it was expected that a history of 
violent CD symptoms, such as aggression towards peers or animals, would be more indicative of 
poorer adjustment and treatment outcome than would its absence. Additionally, the present study 
sought to examine a range of treatment outcome dimensions, including treatment retention and 
adherence, drug use, and functioning across several domains, including social, occupational, and 
psychiatric. It is important to note that in addition to comparing variables pre- and post-
treatment, adjustment to treatment was also included in the analyses. That is, data were collected 
at intake, during, and at the termination of treatment. As such, the term treatment outcome refers 
to functioning during and at the conclusion of treatment. 
Method 
The data used for the current study were collected as part of a larger opioid treatment 
project (Amass, Kamien, Branstetter, & Mikulich, 2000) in collaboration with the University of 
Colorado Health Science Center. From July 17, 1997 through September 3, 1999, the study was 
conducted at The Vine Street Center, an adult opioid outpatient treatment program located in 
Denver, Colorado. All data, including the data for the present study, were entered into the 
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database without any protected health information (PHI) from which the participants could be 
directly identified.  
The project was a 16 week double-blind, double-dummy, randomized clinical trial 
evaluating the effects of pharmacological treatments on opioid dependence. Minimum likelihood 
allocation was used to randomly assign participants into one of four groups evaluating the effects 
of: (1) 8 mg of buprenorphine and 2 mg naloxone; (2) 16 mg buprenorphine and 4 mg naloxone; 
(3) 45 mg methadone; and (4) 90 mg methadone. Additionally, all participants received an hour 
of individualized behavioral counseling every week for the duration of the study and were 
offered group counseling sessions as well.  
Participants  
 One-hundred-five adults (85 male), solicited through Denver newspaper, poster 
advertisements, and referred from similar local treatment programs consented to participate in 
the study. In order to qualify, all individuals were required to be at least 18 years-old, in good 
health, and meet DSM-IV criteria for opioid dependence and FDA criteria for methadone 
treatment. Participants currently using heroin, prescription opioids, or receiving methadone 
maintenance treatment were included. Exclusion criteria included active psychosis, bipolar 
symptoms, organic psychiatric disorders, or significant medical illness. Participants were also 
permitted from participating if they were prescribed mediation which potentially could be 
abused. After being informed of the study and its respective protocol, participants provided 
written informed consent. The mean age of the sample was 39.6 years (SD = 10.8) with a range 
of 18 to 63 years of age at intake. The sample consisted of 53% Caucasian, 26% Latino, 20% 
African-American, and 1% Asian or Pacific Islander. Years of opiate use ranged from 1 to 43 
years, (M = 11.7, SD = 10.8). A total of 66% of the participants were legally employed and 72% 
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had a history of methadone treatment. Thirty-eight percent of the sample were never married, 
28% divorced, 19% married, 11% separated, and 5% widowed.  
As indicated by the diagnostic interview, 63 of the 105 participants (60%) qualified for a 
childhood CD diagnosis. Of the participants with CD, 39 of 63 (62%) reported prior aggressive 
symptoms and were classified as violent CD. As a result of participant dropout, 57 of 105 
participants remained at 8 weeks and 50 remained at the conclusion of the 16 week treatment. 
Measures 
Diagnostic Interview. Portions of the Diagnostic Interview Schedule for DSM-IV 
diagnosis (DIS-IV; Robins, Cottler, Bucholz, Compton, & Rourke, 2000) were conducted for all 
participants to assess for Conduct Disorder (Section O). Participants completed a face-to-face 
interview conducted by certified addiction clinicians. The DIS-IV is a structured diagnostic 
interview characterized by short, simple questions which can typically be answered with a ‘yes’ 
or ‘no’ response. Participants were given ten dollars upon successful completion of the 
interview. In previous studies, test-retest reliability for the DIS-IV ranged from satisfactory to 
excellent and there was good agreement with versions of the DIS and separate clinician diagnosis 
(Helzer et al., 1985). Forms of the DIS have been used in multiple past studies in order to 
accurately diagnose CD and Antisocial Personality Disorder (i.e., Ridenour et al., 2002; Darke, 
Kaye, & Finlay-Jones, 1998). 
  Substance Abuse. Computerized versions of the psychoactive substance disorder sections 
of the DSM-IV Criteria Checklist (modified from Hudziak et al., 1993) were administered in 
order to assess for opioid dependence. The checklist is a semi-structured evaluation shown to 
accurately assess major DSM-IV mental health disorders. It has been shown to demonstrate 
acceptable diagnostic agreement with other validated mental health evaluations (Janca, Robins, 
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Bucholz, Early, & Shayka, 1992). Only participants meeting for opioid dependence were 
permitted to participate in the study.  
Addiction Severity. The fifth edition of the Addiction Severity Index (ASI; McLellan et 
al., 1992) was administered. The ASI is a semi-structured interview designed to assess a range of 
symptoms and behaviors of drug and alcohol users. Additionally, demographic variables, such as 
age, race, and religious preference are also queried with this measure. One can typically 
administer the 161 item index in 30-45 minutes. The ASI assesses functioning in six areas: (1) 
medical, (2) employment/support, (3) alcohol/drug use, (4) legal, (5) family/social relationships, 
and (6) psychiatric. The ASI yields composite scores for each areas ranging from 0 to 1, with 
higher scores indicating more severe impairment. Given the nature of the present study, separate 
ASI scores were calculated for alcohol and drug use. Studies have demonstrated high levels of 
internal consistency (.68), test-retest reliability (.92), inter-rater reliability (up to .96), 
correlations with other measures of SUD and impairment (up to .73), and sensitivity and 
specificity for alcohol (.84 and .93, respectively) and drug abuse (.91 and .92, respectively;  
McLellan et al., 1985; Hodgins & el-Guebaly, 1992; Appleby, Dyson, Altman, & Luchins, 
1997). The ASI was administered at intake, 8 weeks, and 16 weeks into the study. 
Urine Sample Analysis. Three times each week, urine samples were collected. Each of the 
samples was analyzed for the presence of opioids. Once each week, one of the following 
substances was randomly chosen to be analyzed as part of the urine sample: cocaine metabolites, 
amphetamines, benzodiazepines, barbiturates, or cannabinoids. To measure opioid abstinence, 
number of opioid-negative urine samples (“clean” samples) and ratio of negative samples to total 
samples scheduled (absent samples included) were calculated. 
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 Treatment Retention. Treatment retention was calculated as the number of days each 
participant remained active in the study. 
Procedure 
Prior to enrollment, participants completed a comprehensive intake interview to 
determine study eligibility and were administered the ASI. This interview was conducted in a 
two to three hour session the day of enrollment and completed on the same or next day. Data 
regarding treatment adjustment were collected throughout the study and calculated following 
participant completion. The DIS-IV was administered during the first two weeks of study 
participation and ten dollars was given upon its completion. 
Results 
Participant dropout and correction of non-normal data characteristics  
Of the 105 participants screened at intake, 57 remained after 8 weeks and 50 remained for 
the complete 16-week treatment program. Given the missing data resulting from a high rate of 
dropout (52%) and potential abnormal distributions, results were examined for any non-normal 
characteristics. 
All data were initially screened for the presence of outliers and problems of skew or 
kurtosis. Data identified as outliers were reassigned to a value equaling the 75th percentile of the 
distribution plus 1.5 times the interquartile range. For outliers falling below the 25th percentile, 
the same formula was used with the 25th percentile replacing the 75th percentile and subtraction 
in place of addition. Next, using procedures advocated by Behrens (1997), variables with a skew 
greater than 3 or kurtosis greater than 10 were transformed using either inverse, inverse squared, 
square root, log 10, or log e transformations. These transformations resulted in more normally 
distributed scores with acceptable skew and kurtosis.  
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A return-to-baseline technique was used for all missing data. It assumes that once no 
longer receiving treatment, the participant’s scores and drug use will regress to the assessed 
pretreatment intake figure. The return-to-baseline procedure is a highly conservative estimate for 
accounting for missing data as it is based on the assumption that individuals who drop out of a 
SUD treatment program, are likely to relapse to pretreatment substance use rates. This method of 
imputing missing data, unlike similar methods (e.g., last value carried forward), assumes that 
those who drop out of treatment do not sustain any gains they made during the course of 
treatment because dropout from such programs often indicate full relapse. This method for 
missing data imputation was selected for several reasons. First, evidence has emerged which 
suggests that traditional methods of dealing with missing data (e.g., listwise-deletion) can result 
in “drastically changed magnitudes or incorrect signs of the estimates of causal effects or 
descriptive inferences” (King, Honaker, Joseph, & Scheve, 1998, p. 4) and can result in 
discarding a large portion of useful data (Duncan, Duncan, & Strycker, 2006). Additionally, this 
method was selected because common methods of estimating a missing value (e.g., group mean) 
use no information specific to the individual missing the data and have also been shown to result 
in biased estimates (Engels & Diehr, 2003). Because of these findings, the return-to-baseline 
method was selected as the most conservative estimation for missing data imputation using 
values based on each individual and not group means or values.   
CD and Poor Treatment Outcome 
ASI scores. A repeated-measures analysis of variance (ANOVA) was performed to 
examine differences in summed and ASI composite scores over time among participants with (n 
= 63) and without (n = 42) a CD diagnosis. A significant effect of time was found for summed 
ASI score, F(2, 102) = 7.68, p < .01. Such an improvement was expected given the treatment 
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received by the participants. An interaction effect of Summed ASI Score X CD diagnosis was 
found to approach significance, F (2, 102) = 2.49, p = .09. Follow-up tests indicate that 
participants without CD significantly improved from intake to 16 weeks where those with CD 
did not improve. Approaching significance, intake employment/support composites among CD 
participants indicated higher scores prior to treatment, F (1, 103) = 2.86, p = .09. Refer to Table 
1 for comprehensive results. 
Drug use. A repeated-measures ANOVA was conducted to evaluate differences in drug 
use among participants with and without a CD diagnosis throughout the 16-week treatment 
period. As illustrated in Table 2, over the course of treatment, there was a significant interaction 
effect of Cocaine Use X CD Diagnosis, F (2, 102) = 4.00, p < .05. Pairwise comparison follow-
up tests indicated that participants with CD improved from intake to 8 weeks where those 
without CD did not improve markedly throughout treatment. However, among both comparison 
groups, there were no differences in intake cocaine use and use at the conclusion of treatment. 
Similarly, there was an Amphetamine Use X CD Diagnosis interaction effect which approached 
significance, F (2, 102) = 2.54, p = .08. However, contrary to cocaine use, follow-up tests 
demonstrated that the absence of a CD diagnosis led to amphetamine use improvement from 8 to 
16 weeks where a CD diagnosis indicated no improvement over the course of treatment. A one-
way ANOVA demonstrated differences approaching significance in sedative use over the 30 
days prior to intake.  Participants without CD reported using sedatives more frequently, F (1, 
102) = 3.03, p = .09.   
Treatment retention and urine analyses. A one-way ANOVA was conducted to examine 
differences between treatment retention and urine sample analyses among participants with and 
without a CD diagnosis. No significant differences were found between treatment retention rates 
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of the two groups, F (1, 103) = .11, p = .74. An analysis of the means and standard deviations 
indicate a high rate of variability in the treatment retention of participants with CD (M = 75.8 
days; SD = 47.6 days) and without CD (M = 78.9; SD = 43.0). The large range in dropout (R = 
113 and 110 days, respectively) may have also contributed to the results. Similarly, no 
significant differences were found in the number of clean urine samples or percentage of clean 
urine samples provided, F (1, 103) = .07, p = .79 and F(1, 103) = .00, p = 1.00, respectively. 
Similar to treatment outcome, there were high rates of variability, with the standard deviation 
approaching or greater than the mean. 
Severity of CD 
 ASI scores. A hierarchical multiple regression analysis was conducted to analyze the 
effect of number of CD symptoms on ASI composite scores at the conclusion of the 16-week 
treatment, controlling for intake scores. Table 3 demonstrates that CD severity was shown to 
significantly affect ASI psychiatric composite scores, F(1, 101) = 4.20, p < .05, R2 change = .02, 
final model R2 = .57. Beta weights indicate that as CD severity increases, so does psychiatric-
related impairment, β = .13. A linear regression was conducted to determine the effect of number 
of CD symptoms to intake ASI composites. CD severity was found to positively relate to intake 
employment/support composite scores, F(1, 103) = 6.37, p = .01, adjusted R2 = .05, β = .24.  
Drug use. A hierarchical multiple regression analysis was conducted in order to calculate 
the relative influence of CD symptoms on drug use from intake to 16 weeks while controlling for 
intake drug use. Results indicate that the number of CD symptoms was positively associated with 
rates of alcohol intoxication, independent of use at intake, F(1, 102) = 6.26, p = .01, R2 change = 
.03, final model R2 = .52, β = .17. The effect of CD severity on sedative and cocaine use 
approached significance, F(1, 101) = 3.04, p =.08, R2 change = .02, final model adjusted R2 = 
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.33, β = -.14 and F(1, 102) = 2.82, p =.10, R2 change = .01, final model adjusted R2 = .51, β = -
.12, respectively. As the number of CD symptoms increased, sedative and cocaine use were more 
likely to decrease. A linear regression analysis did not find any link between CD severity and 
drug use recorded at intake.  
Treatment retention and urine analyses. A linear regression was conducted to determine 
the relation of CD severity on treatment retention. Treatment retention was not shown to be 
related to CD severity, F(1, 103) = .88, p = .35. Similarly, CD severity was not shown to predict 
number of clean urine samples or percentage of clean urine samples provided, F(1, 103) = .03, p 
= .86 and F(1, 103) = .04, p= .85, respectively.  
Prior Violent Behavior 
ASI scores. All participants qualifying for a childhood CD diagnosis were categorized as 
either violent (n = 39) or nonviolent (n = 24) based upon a history of aggressive behavior as 
measured by diagnostic report. A one-way ANOVA was utilized to compare the number of CD 
symptoms among participants with violent or nonviolent CD. Violent CD participants had 
significantly more CD symptoms than the nonviolent CD participants, with means of 6.03 (SD = 
2.20) and 4.04 (SD = 1.02) symptoms, respectively, F(1, 60) = 17.96, p = .00. A repeated-
measures ANOVA was conducted in order to examine differences in ASI scores over time 
among participants classified with violent or nonviolent CD. There was shown to be a main 
effect of time, as summed ASI scores generally decreased over time for both groups, F(2, 59) = 
3.78, p < .05. Table 5 illustrates that no improvement differences were found between the two 
groups’ summed ASI scores over time, F(2, 59) = .20, p = .82 or among any ASI composite 
scores.  A one-way ANOVA was conducted and found significant differences in the 
employment/support composite scores at intake, F(1, 60) = 4.01, p = .05 with the violent CD 
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group obtaining higher scores, indicating more impairment. Moreover, differences in the 
psychiatric composite at intake approached significance, F(1, 60) = 3.38, p = .07 with the 
nonviolent CD group obtaining higher scores. 
Drug use. A repeated-measures ANOVA was conducted to evaluate differences in drug 
use of participants with violent and nonviolent CD over the course of treatment. Table 6 displays 
no significant differences between the two groups regarding drug use improvement. Differences 
in cocaine use prior to intake approached significance, F(1, 60) = 3.15, p = .08. Participants 
classified with violent CD used cocaine less frequently than participants with nonviolent CD. 
Otherwise, no differences were found regarding drug use at intake among participants with 
violent and nonviolent CD.  
Treatment retention and urine analyses. A one-way ANOVA was conducted to examine 
any differences between treatment retention and urine sample analyses among participants with 
violent or nonviolent CD. No significant differences were found between treatment retention 
rates of the two CD groups, F(1, 60) = .33, p = .57. Additionally, no differences were found in 
the number of clean urine samples or percentage of clean samples provided, F(1, 60) = .01, p = 
.91 and F(1, 60) = .00, p = .99, respectively. As discussed in the analysis of the effects of a CD 
diagnosis, due to the large range of dropout, considerable variability was present in these results, 
which may help clarify the low F values.   
Discussion 
 As part of a drug treatment program, opioid dependent adults were given a diagnostic 
interview to determine if, as a child, they qualified for a CD diagnosis. Data regarding CD 
diagnosis, number of CD symptoms, and prior aggressive behavior were evaluated with multiple 
treatment outcome variables. In accordance with Hser and colleagues (2003), there were 
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supporting data that over the course of treatment, participants with CD experienced poorer 
improvement from intake to the end of treatment in regards to summed ASI scores and better 
improvement from intake to 8 weeks concerning cocaine use. As one’s CD severity increased, 
psychiatric related impairment, as measured by ASI composite scores, increased as well. 
Additionally, more CD symptoms led to poorer rates of alcohol intoxication improvement and 
better improvement for sedative and cocaine use. In comparing participants with CD with and 
without a history of violent behavior, there did not appear to be any differences in treatment 
outcome, although participants with prior violent behavior did on average report more CD 
symptoms. In general, there is support that a history of CD and/or increased number of CD 
symptoms may lead to different presenting and treatment outcome characteristics, both positive 
and negative, than a comparison group. While not varying in treatment outcome, participants 
with a history of CD and prior violent behavior were found to have different intake 
characteristics than participants with a history of CD in the absence of aggressive behavior. 
CD and Poor Treatment Outcome 
 Prior to any intervention, differences emerged demonstrating an association between 
participants with CD and increased ASI employment/support composite scores and sedative use 
over the 30 days prior to intake. It may be that childhood CD symptoms, such as violence 
towards others, stealing, or lying may still presently occur and would likely make it difficult to 
attain a job and support one’s self, thus leading to low scores on the respective ASI composite. 
The employment/support composite, contrary to most other ASI queries, may rely on personal 
attributes such as interpersonal trust and reliability which may be difficult to obtain if one is 
behaving in accordance with CD symptoms. Regarding sedative use, it may be that the calming 
and tranquilizing nature of sedatives are more attractive to the CD population. These effects may 
                                                                                                        
 21 
 
be a desirable contrast to the potentially aggressive or hostile cognitions and behaviors that may 
accompany CD. Needless to say, in order to better understand this relation, additional studies are 
to be conducted in this area of research.  
 ASI scores. Over the course of the 16-week treatment, differences were found in 
improvement rates of summed ASI composite scores between participants with and without CD. 
It may be that the groups’ differing incoming characteristics led to improvement variation during 
SUD treatment. Given the presenting impairment in the employment/support domain, it can be 
theorized that the lack of a steady job or an ability to support one’s basic needs may have 
prevented participants with CD from retaining improvement over treatment. In the absence of the 
stability of a daily routine, other facets of one’s life, as measured by the ASI, may also suffer. 
Another explanation may be that participants with a history of CD continue to perform the 
respective maladaptive behaviors and this is reflected in the composite scores of the ASI. For 
instance, participants continuing to present with theft will have difficulties in the legal domain or 
those defying major societal norms may experience impairment with family and social 
relationships. Cumulatively, relatively poor improvement of ASI scores demonstrate that SUD 
treatment was not as effective for participants with CD in reducing drug and alcohol related 
impairment as compared to those without CD.  
 Drug use. Over the course of treatment, results demonstrated different improvement rates 
of amphetamine and cocaine use as a function of a CD diagnosis. Regarding cocaine use, 
participants with CD underwent improvement from intake to 8 weeks of treatment, while the 
same population had poorer amphetamine use improvement rates from 8 to 16 weeks in 
comparison to candidates without CD. Perhaps the high likelihood of comorbid CD and ADHD 
(McMahon & Wells, 1998) in childhood may be involved in the variation of amphetamine use. 
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Since many psychotropic medications for ADHD are classified as amphetamines (e.g., Adderall) 
and demonstrated to be effective in treating ADHD symptoms (James et al., 2001), the benefits 
of amphetamines may outweigh some of the risks and thus, reducing its use may not be 
considered as beneficial. Considering CD symptoms are often seen with ADHD, long-term 
amphetamine treatment may be more difficult to obtain with conventional drug treatment. 
Indeed, a 28 year longitudinal study found a significant correlation between an ADHD diagnosis 
and amphetamine dependency (Lambert, 2005). Even when controlling for other possible 
confounding variables, children with ADHD were more likely to become addicted to 
amphetamines than peers without ADHD. However, that same study also found no significant 
relation between childhood conduct problems and amphetamine use.  
A theory to explain greater cocaine use improvement among participants with CD may be 
the effects of a limited budget. As represented by higher impairment in the employment/support 
domain, participants with CD reported more difficulties supporting themselves financially. 
Without sufficient monetary support, purchasing cocaine may be more difficult and lead to 
amplified financial difficulties. Thus, this population may be more receptive to drug treatment 
and the monetary gains experienced accordingly may provide additional motivation to reduce its 
use. As such, Cleveland (2006) concluded that hard-core drug users are especially responsive to 
the overall cost of their drug of choice and will increase or decrease their use accordingly. 
Surely, more research needs to be done on this topic, but variations among presenting 
employment/support impairment may help explain the different results among the two 
populations. 
 General conclusions. Given the limited differences at intake regarding ASI scores and 
drug use over the past 30 days, it appears that within the population of substance abusers seeking 
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treatment, a diagnosis of CD may not exert as much influence as established in past studies. An 
explanation for this may be the nature of the comparison group. In past studies (e.g., Fergusson 
et al., 1993), researchers compared participants with CD to relatively unimpaired individuals. 
However, in the current study, all participants were opioid dependent and most reported a history 
of psychological, social, and emotional impairment. Thus, discriminating the groups based upon 
CD may not lead to as much measurable differences between the groups as in past studies, based 
upon the history of the participant pool. This may also play a part in explaining why the CD 
group unexpectedly improved in certain measures (e.g., cocaine use). Within this population, 
perhaps a diagnosis of CD only alters outcome in very specific aspects of SUD treatment.  
Severity of CD 
 ASI scores. As Crowley and colleagues (1998) reported, as the number of CD symptoms, 
or severity, increases, one’s treatment outcome is likely to worsen. To a degree, these results 
were supported by the current study. In addition to incoming differences within the 
employment/support composite, participants with more severe CD obtained significantly higher 
ASI psychiatric composite scores over the course of treatment. The psychiatric composite results 
are plausible; reporting more CD symptoms appears to demonstrate more mental health 
difficulties which may not be as receptive to treatment. With this impairment, a prospective 
employer may be less likely to hire or continue to retain a staff member displaying these 
maladaptive symptoms. Such results suggest that altering treatment to emphasize improvement 
within the psychiatric and employment/support domains may be a beneficial addition to 
conventional substance abuse treatment for participants with high CD severity.  
 Drug use. With additional CD symptoms, researchers were more likely to observe a 
reduction in cocaine and sedative use over the course of treatment. If there is validity to the 
                                                                                                        
 24 
 
hypothesis that differences in the employment/support domain at intake led to financial 
restrictions, then particularly expensive drugs, such as cocaine and sedatives, would be more 
likely to improve. Decreasing cocaine and sedative use may be more appealing to participants 
with increased CD symptoms due to presenting difficulties in the ability to support one’s self.  
Alcohol intoxication rates, on the other hand, increased along with CD severity. Possibly 
there is a certain effect of alcohol intoxication which is appealing to participants with many CD 
symptoms. A viable explanation is that alcohol, in contrast to the other drugs assessed, can be 
legally used as a mean to intoxicate one’s self. Participants with high CD severity may have been 
more likely to substitute alcohol in place of other drugs, namely heroin. Since all participants 
were opioid dependent and opioid use generally decreased over the course of treatment, it is 
theorized that those with more CD symptoms (and higher impairment) coped with their 
withdrawal through the use of alcohol. The current study’s results demonstrate that alcoholism 
therapy should become more integrated in SUD treatment, particularly with participants with 
severe CD. It is of interest to report that despite established differences in drug use and ASI 
composite improvement, effect sizes generally demonstrate that the role of CD severity is a 
small, albeit meaningful, variable in SUD treatment outcome. ASI composite scores and drug use 
at the start of treatment played a far larger role in predicting their respective post-treatment 
impairment than did CD severity. For instance, increased CD symptoms accounts for just 2% of 
the variability of post-treatment psychiatric impairment, independent of intake scores. However, 
within this population, the results illustrate the need to provide enhanced treatment for clients 
presenting with high levels of impairment, independent of CD severity. 
 General conclusions. Although much is still unknown about CD severity and substance 
abuse treatment, it may be a broad measure of the disorder’s detrimental effects. If so, it may 
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behave similarly to depression or anxiety, where clients entering treatment with higher levels of 
impairment (Beutler, Blatt, Alimohamed, Levy, & Angtuaco, 2006) or disorder severity 
(Newman, Crits-Christoph, Gibbons, & Erickson, 2006), respectively, are less likely to improve 
with treatment. It is likely that assessing the more intricate details of CD will provide more 
insight to the most effective form of SUD treatment.   
Prior Violent Behavior 
 The final analyses were conducted to examine any differences in treatment outcome 
among participants classified as violent or nonviolent CD. That is, among participants with CD, 
the distinction was based upon reporting at least one symptom from the aggression subgroup as 
listed by the DSM-IV (APA, 2000). In short, no significant differences were found in terms of 
the comparison groups’ response to treatment. There were, however, initial differences between 
the groups as ascertained by self-report at intake. Prior to treatment, employment/support ASI 
composite scores of the participants with violent CD was higher and the psychiatric composite 
lower than their nonviolent counterparts. Additionally, participants with violent CD used cocaine 
less often than participants with nonviolent CD prior to intake. Additionally, participants 
classified with violent CD had considerably more CD symptoms than those classified with 
nonviolent CD. Such a result demonstrates that a history of violent behavior may be indicative of 
increased CD-related impairment.  
 ASI scores and drug use. As seen in comparing participants with and without a history of 
CD, the group presumed to be more impaired fittingly scored higher on the employment/support 
composite of the ASI at intake. Violent behavior, in addition to the interpersonal difficulties that 
may be associated with CD, appears to lower the likelihood of being hired for a job, retaining 
such a job, and supporting one’s self. The results regarding the psychiatric composite of the ASI 
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were more unexpected. Given that the violent CD participants not only had a history of 
aggression, but also significantly more CD symptoms than the nonviolent CD group, it would be 
expected that the violent CD group is more psychiatrically impaired. However, at intake, the 
nonviolent CD group presented with higher psychiatric composite scores. A possible explanation 
may lie in the psychiatric composite queries of various psychological symptoms outside of the 
realm of CD and aggression. Whereas a violent individual may assume his or her impairment lies 
within his or her aggression, nonviolent participants may be more likely to attribute their 
behavioral and cognitive deficits more accurately. In other words, one who does not act violently 
may be better suited to attribute impairment to anxiety or depression. Participants with violent 
CD may be more impaired than the nonviolent group, but the self-reporting nature of the ASI 
produces results that do not suggest the presence of severe problems. As discussed above, the 
effect of financial difficulties may play a part in the presenting differences in cocaine use.  
 General conclusions. Despite some differences prior to treatment, no differences were 
found in regards to treatment outcome or functioning. Whether an individual with CD had a 
history of aggression or not, improvement, as measured by ASI scores, drug use, treatment 
retention, and urine analyses, did not vary statistically over the course of treatment. While 
substance abusers with violent CD did differ at intake from those with nonviolent CD in terms of 
number of CD symptoms, employment/support composite scores, and recent cocaine use, the 
participants’ response to treatment remained similar. Such results demonstrate that substance 
abuse treatment of a client with CD may not need to be adjusted based upon the client’s prior 
violent behavior. Establishing a diagnosis of CD and its severity appears to be sufficient in 
determining necessary adjustments to one’s SUD treatment techniques. Such a procedure does 
not appear to be excessively demanding and, given the current study’s results, may be helpful in 
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improving the target areas of treatment. Within this population, it seems that further analysis of 
one’s CD, in terms of topography of symptoms, may not be necessary in order to improve 
treatment efficacy.  
Limitations 
The most noticeable and detrimental limitation of the current study was the dropout rate 
among the participants. Of 105 initial consenters, only 50 participated in the full, 16-week study. 
Although the population of severe drug abusers appears to be a difficult one to retain over an 
extended period of time, relatively high dropout rates nevertheless likely altered the results and 
possible conclusions. Secondly, given the conservative method of the return-to-baseline missing 
data imputation, differences between comparison groups may have been minimized. Perhaps 
data could have been taken at more frequent intervals, as opposed to only three times over the 
course of the study. Additionally, in the absence of comprehensive ADHD measures, it was 
difficult to provide conclusive support for the theory that certain drugs, such as amphetamines, 
may aid ADHD symptoms through their use. Rather, it was inferred that it was likely some 
participants, due to a CD diagnosis, may also qualify for an ADHD diagnosis. With conclusive 
ADHD assessments, the presence of ADHD and its severity could be confirmed and not 
presumed. 
 Results may have differed if another missing data replacement method, such as mean 
substitution or last observation carried forward, was implemented. Some of the results 
approached but did not reach significance. Although much of the discussion involved the 
implications of data trends (p ≤ .10), given the highly conservative method of data imputation, 
there is more confidence in the differences that were found. Perhaps with a less conservative 
approach, more group differences would achieve accepted levels of significance.  It is also 
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believed that additional participants and/or improved dropout rates would more decisively bring 
about significant results where the current results only approach significance. Lastly, there was 
no long-term follow up data collected. The final data point is the end of treatment—16 weeks  
following intake—and it is unknown of any long-term changes in functioning among the 
participants. With additional longitudinal data collection, differences between comparison 
groups would be apparent and provide additional conclusions regarding SUD treatment outcome. 
Lastly, the use of a retrospective report to self-assess for childhood CD symptoms may lack 
optimal validity. Asking one to provide information about specific behaviors that may have 
occurred decades ago, particularly among an opioid dependent population, is not nearly as 
accurate as tracking the target behaviors as they occur. Although given the present study’s access 
to the respective population, a diagnostic interview may have been feasible and efficient, it is not 
as compelling as other possible data collection methods.  
Conclusions 
The present results suggest that there are underlying differences within the population of 
treatment seeking, substance abusing adults based upon CD diagnosis, its severity, and prior 
violent behavior. Although multiple differences were found among the various comparison 
groups’ ASI scores and drug use, two measures, treatment retention and urine analyses detecting 
the presence of various drugs, did not reveal any differences among any of the comparison 
groups. This may discredit any perceptions that participants with CD, regardless of its severity or 
prior aggressive behavior, will dropout of treatment earlier than others. It seems that a history of 
CD-related behavior may be irrelevant when concerning the treatment retention of an opioid 
dependent adult will remain in treatment. Such a measure, if interpreted in and of itself, may be 
misleading in revealing no differences between comparison groups. The urine analyses mainly 
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dealt with the presence of opioids in the body and were tested three times each week. Once each 
week, a different, randomly selected drug was assessed for as well. As confirmed by urine 
analyses, there were no physiological differences regarding the examined drug use. Such a result 
demonstrates that utilizing urine analyses for the presence of drugs may not suffice as the sole 
measure of impairment. Perhaps future drug treatment programs are better served to use 
alternative measures of substance abuse in addition to the physiological detection of recent drug 
use. As differences in ASI scores demonstrate, there remains drug-related impairment within this 
population despite all indications from urine analyses. Urine sample analyses are one of many 
methods which can be useful in determining if deficits are present. However, given the 
contradictory results between urine sample analyses and other measures of similar constructs, it 
can be inferred that urine analyses, in and of itself, does not provide a comprehensive assessment 
of drug-related impairment with this population. 
 The current study examined the effects of CD on SUD treatment involving a severe, 
substance abusing population and offers a retrospective look as to how CD may be associated 
with improvement. In regards to the study’s implications, it is the hope that the results provide 
insight into creating more effective SUD prevention and treatment programs. Higher summed 
ASI composites, psychiatric symptoms, amphetamine and alcohol intoxication rates, and the 
presenting deficiencies in the employment/support domain as a result of CD and its increased 
severity are all findings which could impact SUD treatment. Additionally, further examining 
why participants expected to be more impaired (e.g., a CD diagnosis, higher CD intensity) were 
more likely to improve in regards to cocaine use may also prove helpful. In examining SUD 
treatment, studies can build upon the present one by scrutinizing optimal treatment options, such 
as a focus on alcohol intoxication reduction or employment skill instruction. These minor 
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additions to standard treatment protocol may be adequate to improve the treatment outcome of 
clients with CD or high CD severity. Further research is required, however, before such changes 
are put into practice. Possibly the most important contribution to the current literature is the 
recognition that CD is a complex disorder which affects the development and treatment of SUD. 
A better understanding of this relation and modifying SUD treatment accordingly will likely 
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Table 1.  
 








Medical    
      No CD (n = 42) .32 (.38) .33 (.40) .29 (.35) 
      CD (n = 63) .24 (.31) .23 (.31) .25 (.31) 
Employment/support    
      No CD .54 (.29)* .44 (.27) .47 (.29) 
      CD .64 (.30)* .57 (.32) .61 (.32) 
Alcohol use    
      No CD .09 (.11) .08 (.10) .07 (.09) 
      CD .09 (.12) .07 (.09) .07 (.10) 
Drug use    
      No CD .24 (.11) .20 (.14) .18 (.13) 
      CD .24 (.12) .18 (.13) .19 (.13) 
Legal    
      No CD .18 (.20) .14 (.19) .12 (.16) 
      CD .17 (.21) .12 (.18) .11 (.14) 
Family/social relationships    
      No CD .19 (.20) .22 (.18) .20 (.19) 
      CD .21 (.21) .23 (.17) .23 (17) 
Psychiatric    
      No CD .13 (.19) .14 (.17) .12 (.15) 
      CD .14 (.17) .15 (.17)  .17 (.17) 
ASI Sum score*    
      No CD 1.67 (.83) 1.55 (.79) 1.43 (.76) 
      CD 1.73 (.70) 1.56 (.67) 1.62 (.63) 




















Repeated-measures ANOVA of drug use over the past 30 days based upon CD diagnosis (raw 
data) 
 
 Intake  
M (SD) 
8 weeks  
M (SD) 
16 weeks  
M (SD) 
Alcohol (days consumed)    
      No CD (n = 42) 6.83 (8.84) 7.55 (10.16) 5.90 (8.08) 
      CD (n = 63) 5.57 (9.10) 5.33 (9.00) 4.92 (8.10) 
Alcohol intoxication    
      No CD 2.62 (6.84) 1.98 (5.29) 1.38 (4.47) 
      CD 2.51 (6.43) 1.40 (4.28) 1.67 (4.83) 
Heroin    
      No CD 25.43 (7.84) 15.21 (13.15) 15.00 (32.36) 
      CD 25.27 (9.85) 15.83 (13.67) 16.51 (13.62) 
Methadone    
      No CD 3.17 (8.07) 2.05 (7.07) 1.33 (5.52) 
      CD 5.00 (10.20) 1.94 (6.65) 2.41 (7.53) 
Opiates    
      No CD 1.92 (6.48) 1.24 (4.17) 1.29 (3.83) 
      CD 1.53 (5.67) 1.42 (5.43) .76 (3.89) 
Barbiturates    
      No CD .00 (.00) .00 (.00) .02 (.15) 
      CD .16 (.96) .18 (.97) .42 (2.12) 
Sedatives    
      No CD .98 (3.53)* 1.48 (4.16) 1.93 (5.74) 
      CD .35 (2.09)* .27 (1.30) .26 (1.10) 
Cocaine**    
      No CD 2.83 (6.36) 3.62 (6.90) 2.95 (5.91) 
      CD 3.98 (6.54) 3.03 (6.22) 2.75 (5.96) 
Amphetamines*    
      No CD .48 (1.95) 1.07 (4.57) .95 (4.84) 
      CD .11 (.48) .11 (.48) .17 (.64) 
Marijuana    
      No CD 4.43 (8.60) 5.24 (9.34) 4.52 (8.78) 
      CD 5.25 (8.71) 4.73 (7.95) 5.46 (9.15) 
Hallucinogens    
      No CD .00 (.00) .00 (.00) .00 (.00) 
      CD .00 (.00) .02 (.13) .06 (.50) 
Multiple drugs    
      No CD 9.86 (10.51) 8.38 (10.33) 6.88 (9.87) 
      CD 10.67 (10.76) 6.86 (8.82) 6.49 (8.52) 
* p ≤ .10; ** p ≤ .05  
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Table 3.  
 




ASI composite β Final Model R2 R2 change 
Medical -.05 .55 .00 
Employment/support .07 .72 .01 
Alcohol .01 .74 .00 
Drugs .09 .38 .01 
Legal .01 .52 .00 
Family/social relationships .08 .35 .01 
Psychiatric .13 .58 .02** 
ASI Sum score .09 .64 .01 
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Table 4.  
 
Hierarchical multiple regression of CD severity and days of drug use over the past 30 days, 
controlling for use at intake 
 
Drug β R2 R2 change 
Alcohol .01 .70 .00 
Alcohol intoxication .17 .52 .03*** 
Heroin .10 .21 .01 
Methadone .12 .40 .02 
Opiates -.08 .33 .01 
Barbiturates -.09 .40 .01 
Sedatives -.14 .34 .02* 
Cocaine -.12 .52 .01* 
Amphetamines .00 .41 .00 
Marijuana .03 .80 .00 
Multiple drugs .02 .46 .00 
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Table 5.  
 









Medical    
      Nonviolent CD (n = 24) .20 (.27) .20 (.26) .24 (.27) 
      Violent CD (n = 39) .25 (.32) .24 (.33) .24 (.31) 
Employment/support    
      Nonviolent CD .53 (.35)** .47 (.36) .49 (.35) 
      Violent CD .69 (.26)** .62 (.28) .67 (.28) 
Alcohol use    
      Nonviolent CD .07 (.10) .06 (.09) .07 (.09) 
      Violent CD .10 (.13) .08 (.10) .08 (.10) 
Drug use    
      Nonviolent CD .26 (.23) .19 (.12) .19 (.10) 
      Violent CD .23 (12) .18 (.13) .19 (.13) 
Legal    
      Nonviolent CD .12 (.20) .11 (.17) .09 (.13) 
      Violent CD .20 (22) .13 (.19) .12 (.15) 
Family/social relationships    
      Nonviolent CD .26 (.23) .23 (.19) .23 (.17) 
      Violent CD .19 (.19) .23 (.19) .23 (.17) 
Psychiatric    
      Nonviolent CD .19 (.17)* .20 (.15) .19 (.15) 
      Violent CD .11 (.16)* .13 (.17) .15 (.18) 
ASI Sum score    
      Nonviolent CD 1.63 (.85) 1.47 (.69) 1.49 (.62) 
      Violent CD 1.77 (.70) 1.61 (.66) 1.67 (.62) 
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Table 6.  
 
Repeated measures ANOVA of drug use over the past 30 days based upon prior violent, CD-
related behavior (raw data) 
 
 Intake  
M (SD) 
8 weeks  
M (SD) 
16 weeks  
M (SD) 
Alcohol (days consumed)    
      Nonviolent CD (n = 24) 3.96 (7.45) 4.70 (8.36) 4.48 (6.99) 
      Violent CD (n = 39) 6.67 (9.97) 5.85 (9.46) 5.31 (8.82) 
Alcohol intoxication    
      Nonviolent CD 1.04 (3.15) .48 (1.20) .35 (.65) 
      Violent CD 3.44 (7.70) 1.97 (5.31) 2.49 (6.00) 
Heroin    
      Nonviolent CD 26.26 (7.71) 15.96 (13.63) 16.91 (13.26) 
      Violent CD 24.56 (11.05) 15.90 (14.02) 16.69 (13.91) 
Methadone    
      Nonviolent CD 6.48 (11.79) .00 (.00) 2.61 (8.64) 
      Violent CD 4.23 (9.33) 3.12 (8.27) 2.36 (7.01) 
Opiates    
      Nonviolent CD 1.70 (6.28) 1.65 (6.28) .39 (1.20) 
      Violent CD 1.47 (5.42) 1.32 (5.00) 1.00 (4.89) 
Barbiturates    
      Nonviolent CD .13 (.63) .13 (.63) .13 (.63) 
      Violent CD .18 (1.14) .19 (1.15) .61 (2.66) 
Sedatives    
      Nonviolent CD .00 (.00) .00 (.00) .09 (.29) 
      Violent CD .58 (2.66) .45 (1.64) .24 (1.15) 
Cocaine    
      Nonviolent CD 5.30 (6.70)* 3.91 (6.13) 2.78 (5.13) 
      Violent CD 3.31 (6.47)* 2.59 (6.37) 2.77 (6.53) 
Amphetamines    
      Nonviolent CD .22 (.67) .22 (.67) .26 (.75) 
      Violent CD .05 (.32) .05 (.32) .13 (.57) 
Marijuana    
      Nonviolent CD 4.39 (7.91) 4.61 (7.72) 5.52 (9.45) 
      Violent CD 5.90 (9.28) 4.90 (8.26) 5.44 (9.21) 
Hallucinogens    
      Nonviolent CD .00 (.00) .04 (.21) .00 (.00) 
      Violent CD .00 (.00) .00 (.00) .10 (.64) 
Multiple drugs    
      Nonviolent CD 10.22 (10.66) 6.35 (8.48) 4.57 (7.15) 
      Violent CD 11.21 (10.94) 7.33 (9.16) 7.79 (9.16) 
* p ≤ .10  
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